FDA Approves Lumryz for Treatment of Narcolepsy

Anne Marie Morse, DO, of Geisinger Health, discusses the U.S. Food and Drug Administration (FDA) approval of Lumryz (sodium oxybate) for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy ages 7 years and older.    ...

Effects of Inebilizumab to Treat Myasthenia Gravis

Richard Nowak, MD, and Director of Myasthenia Gravis Clinic at Yale University, discusses data from the MINT study for myasthenia gravis (MG).     MG is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal muscles. The...

Efgartifimod in Seronegative Myasthenia Gravis

Ratna Bhavaraju-Sanka, MD, Chief of Neuromuscular Medicine at UT Health San Antonio, discusses Vyvgart’s (efgartigimod alfa) impact on myasthenia gravis (MG) patients.     MG is a chronic autoimmune neuromuscular disease characterized by weakness of the...